Evidence map›Paper›PMID 35066161›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

HIV incidence and prevalence among adults aged 15-64 years in Rwanda: Results from the Rwanda Population-based HIV Impact Assessment (RPHIA) and District-level Modeling, 2019.

Sabin Nsanzimana, Gallican Nshogoza Rwibasira, Samuel Sewava Malamba, Gentille Musengimana, Eugenie Kayirangwa, Sasi Jonnalagadda, Erika Fazito Rezende, Jeffrey W Eaton, Veronicah Mugisha, Eric Remera and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sabin NsanzimanaMinistry of Health, Rwanda Biomedical Centre.
Gallican Nshogoza RwibasiraICAP at Columbia University.
Samuel Sewava MalambaUS Centers for Disease Control and Prevention.
Gentille MusengimanaUS Centers for Disease Control and Prevention. Electronic address: qvx2@cdc.gov.
Eugenie KayirangwaUS Centers for Disease Control and Prevention.
Sasi JonnalagaddaUS Centers for Disease Control and Prevention.
Erika Fazito RezendeICAP at Columbia University.
Jeffrey W EatonMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Veronicah MugishaICAP at Columbia University.
Eric RemeraMinistry of Health, Rwanda Biomedical Centre.
Semakula MuhamedMinistry of Health, Rwanda Biomedical Centre.
Augustin MulindabigwiMinistry of Health, Rwanda Biomedical Centre.
Jared OmoloUS Centers for Disease Control and Prevention.
Lubbe WeisnerUCT Pharmacology Research Laboratory, City of Cape Town, Western Cape, South Africa, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Carole MooreUS Centers for Disease Control and Prevention.
Hetal PatelUS Centers for Disease Control and Prevention.
Jessica E JustmanICAP at Columbia University.

Funding

CGH CDC HHS U2G GH001226Intramural CDC HHS CC999999Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

objectivesThe 2018-2019 Rwanda Population-based HIV Impact Assessment (RPHIA) was conducted to measure national HIV incidence and prevalence. District-level estimates were modeled to inform resources allocation.

methodsRPHIA was a nationally representative cross-sectional household survey. Consenting adults were interviewed and tested for HIV using the national diagnostic algorithm followed by laboratory-based confirmation of HIV status and testing for viral load (VL), limiting antigen (LAg) avidity, and presence of antiretrovirals. Incidence was calculated using normalized optical density ≤ 1·5, VL ≥ 1,000 copies/mL, and undetectable antiretrovirals. Survey and programmatic data were used to model district-level HIV incidence and prevalence.

resultsOf 31,028 eligible adults, 98·7% participated in RPHIA and 934 tested HIV positive. HIV prevalence among adults in Rwanda was 3·0% (95% CI:2·7-3·3). National HIV incidence was 0·08% (95% CI:0·02-0·14) and 0·11% (95% CI:0·00-0·26) in the City of Kigali (CoK). Based on district-level modeling, HIV incidence was greatest in the 3 CoK districts (0·11% to 0·15%) and varied across other districts (0·03% to 0·10%).

conclusionsHIV prevalence among adults in Rwanda is 3.0%; HIV incidence is low at 0.08%. District-level modeling has identified disproportionately affected urban hotspots: areas to focus resources.

Indexed as

HIV InfectionsAdolescentAdultCross-Sectional StudiesHumansIncidenceMiddle AgedPrevalenceRwandaYoung AdultHIVIncidenceNaomi modelpopulation-based surveysPrevalenceRwanda

Identifiers

PMID35066161
PMCPMC9069967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.